hERG channel function: Beyond long QT

Article (PDF Available)inActa Pharmacologica Sinica 34(3):329-35 · March 2013with31 Reads
DOI: 10.1038/aps.2013.6 · Source: PubMed
Abstract
To date, research on the human ether-a-go-go related gene (hERG) has focused on this potassium channel's role in cardiac repolarization and Long QT Syndrome (LQTS). However, growing evidence implicates hERG in a diversity of physiologic and pathological processes. Here we discuss these other functions of hERG, particularly their impact on diseases beyond cardiac arrhythmia.

Full-text (PDF)

Available from: PubMed Central, Jan 16, 2014 · License: CC BY-NC-ND
    • "ELK channels modulate neuronal excitability, but little is known of their specific functions (Becchetti, et al., 2002). ERG channels have diverse biological and pathogenic roles in many tissues, including the heart, brain, smooth muscle, pancreas and tumors (Babcock and Li, 2013). In the human heart, hERG1 channels "
    [Show abstract] [Hide abstract] ABSTRACT: Ginsenoside 20(S)-Rg3 (Rg3) is a steroid glycoside that induces human ether-a-go-go-related gene 1 (hERG1) channels to activate at more negative potentials and to deactivate more slowly than normal. However, it is unknown whether this action in unique to hERG1 (Kv11.1) channels. Here we compare and contrast the mechanisms of actions of Rg3 on hERG1 with three other members of the ether-a-go-go (EAG) K(+) channel gene family, including EAG1 (Kv10.1), ERG3 (Kv11.3), and ELK1 (Kv12.1). All four channel types were heterologously expressed in Xenopus laevis oocytes, and K(+) currents were measured using the two-microelectrode voltage-clamp technique. At a maximally effective concentration, Rg3 shifted the half-point of voltage-dependent activation (V0.5) by (-)14 mV for ERG1 (EC50 = 414 nM), (-)20 mV for ERG3 (EC50 = 374 nM), (-)28 mV for EAG1 (EC50 = 1.18 μM) and more than (-)100 mV for ELK1 (EC50 = 197 nM) channel currents. Rg3 also induced a profound slowing of ERG1, ERG3 and ELK1 channel deactivation and an accelerated rate of EAG1 channel activation. A Markov model was developed to simulate hELK1 channel gating and the effects of Rg3 on the voltage dependence of activation of these channels. Understanding the mechanism underlying the action of Rg3 may facilitate the development of more potent and selective EAG family channel activators for therapeutic use.
    Article · Aug 2016
    • "Ion-channels are pore-forming, membrane-bound proteins , permeable to specific ions, which play fundamental roles in inter-and intracellular communication and neuronal excitability. As such, ion-channels have been subjected to rigorous research investigations into a very broad range of important therapeutic areas since numerous disease states are associated with their dysfunction (Babcock & Li, 2013; Kaczorowski, McManus, Priest, & Garcia, 2008; Kullmann, 2010). Adding to this point, roughly 15% of the most successfully marketed pharmaceutical drugs target ion-channels (Overington, Al-Lazikani, & Hopkins, 2006) with a market value in excess of $10 billion (USD) (Terstappen et al., 2010). "
    [Show abstract] [Hide abstract] ABSTRACT: Adverse CNS effects account for a sizeable proportion of all drug attrition cases. These adverse CNS effects are mediated predominately by off-target drug activity on neuronal ion-channels, receptors, transporters and enzymes - altering neuronal function and network communication. In response to these concerns, there is growing support within the pharmaceutical industry for the requirement to perform more comprehensive CNS safety testing prior to first-in-human trials. Accordingly, CNS safety pharmacology commonly integrates several in vitro assay methods for screening neuronal targets in order to properly assess therapeutic safety. One essential assay method is the in vitro electrophysiological technique - the 'gold standard' ion channel assay. The in vitro electrophysiological method is a useful technique, amenable to a variety of different tissues and cell configurations, capable of assessing minute changes in ion channel activity from the level of a single receptor to a complex neuronal network. Recent advances in automated technology have further expanded the usefulness of in vitro electrophysiological methods into the realm of high-throughput, addressing the bottleneck imposed by the manual conduct of the technique. However, despite a large range of applications, manual and automated in vitro electrophysiological techniques have had a slow penetrance into the field of safety pharmacology. Nevertheless, developments in throughput capabilities and in vivo applicability have led to a renewed interest in in vitro electrophysiological techniques that, when complimented by more traditional safety pharmacology methods, often increase the preclinical predictability of potential CNS liabilities.
    Article · Apr 2016
    • "Inhibition of Kv11.1 results in reduced proliferation of cancer cell lines and activation of an apoptotic event resulting in cell death44454647. The human ether à go-go-related gene 1 (hERG1/KCNH2) encodes for the Kv11.1 channel that is expressed in several organs in normal adults, including in heart, brain and hematopoietic cells404142. Interestingly, it has been observed that, expression Kv11.1 is selectively upregulated in a variety of cancers [43] and several studies have shown that Kv11.1 channel can be a potential novel biomarker for cancer invasion and survival. "
    [Show abstract] [Hide abstract] ABSTRACT: Changes of the electrical charges across the surface cell membrane are absolutely necessary to maintain cellular homeostasis in physiological as well as in pathological conditions. The opening of ion channels alter the charge distribution across the surface membrane as they allow the diffusion of ions such as K + , Ca ++ , Cl − , Na +. Traditionally, voltage-gated ion channels (VGIC) are known to play fundamental roles in controlling rapid bioelectrical signaling including action potential and/or contraction. However, several investigations have revealed that these classes of proteins can also contribute significantly to cell mitotic biochemical signaling, cell cycle progression, as well as cell volume regulation. All these functions are critically important for cancer cell proliferation. Interestingly, a variety of distinct VGICs are expressed in different cancer cell types, including metastasis but not in the tissues from which these tumors were generated. Given the increasing evidence suggesting that VGIC play a major role in cancer cell biology, in this review we discuss the role of distinct VGIC in cancer cell proliferation and possible therapeutic potential of VIGC pharmacological manipulation.
    Full-text · Article · May 2015
Show more